Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy
- PMID: 29895504
- DOI: 10.1016/j.vaccine.2018.06.002
Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy
Abstract
Introduction: In Tuscany, Italy, where a universal immunization program with monovalent meningococcal C conjugate vaccine (MCC) was introduced in 2005, an outbreak of invasive meningococcal disease (IMD) due to the hypervirulent strain of Neisseria meningitidis C/cc11 occurred in 2015-2016, leading to an immunization reactive campaign using either the tetravalent (ACWY) meningococcal conjugate or the MCC vaccine. During the outbreak, IMD serogroup C (MenC) cases were also reported among vaccinated individuals. This study aimed to characterize meningococcal C conjugate vaccines (MenC-vaccines) failures and to estimate their effectiveness since the introduction (2005-2016) and during the outbreak (2015-2016).
Methods: MenC cases and related vaccine-failures were drawn from the National Surveillance System of Invasive Bacterial Disease (IBD) for the period 2006-2016. A retrospective cohort-study, including the Tuscany' population of the birth-cohorts 1994-2014, was carried out. Based on annual reports of vaccination, person-years of MenC-vaccines exposed and unexposed individuals were calculated by calendar-year, birth-cohort, and local health unit. Adjusted (by birth-cohort, local health unit, and calendar-year) risk-ratios (ARR) of MenC invasive disease for vaccinated vs unvaccinated were estimated by the Poisson model. Vaccine-effectiveness (VE) was estimated as: VE = 1-ARR.
Results: In the period 2006-2016, 85 MenC-invasive disease cases were reported; 61 (71.8%) from 2015 to 2016. Twelve vaccine failures occurred, all of them during the outbreak. The time-interval from immunization to IMD onset was 20 days in one case, from 9 months to 3 years in six cases, and ≥7 years in five cases. VE was, 100% (95%CI not estimable, p = 0.03) before the outbreak (2006-2014) and 77% (95%CI 36-92, p < 0.01) during the outbreak; VE was 80% (95%CI 54-92, p < 0.01) during the overall period.
Conclusions: In Tuscany, MenC-vaccine failures occurred exclusively during the 2015-2016 outbreak. Most of them occurred several years after vaccination. VE during the outbreak-period was rather high supporting an effective protection induced by MenC-vaccines.
Keywords: Invasive meningococcal disease; Meningococcal C conjugate vaccine; Outbreak; Vaccine effectiveness.
Copyright © 2018. Published by Elsevier Ltd.
Similar articles
-
Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.Vaccine. 2017 Apr 11;35(16):2025-2033. doi: 10.1016/j.vaccine.2017.03.010. Epub 2017 Mar 18. Vaccine. 2017. PMID: 28318769
-
Interconnected clusters of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11), involving bisexuals and men who have sex with men, with discos and gay-venues hotspots of transmission, Tuscany, Italy, 2015 to 2016.Euro Surveill. 2018 Aug;23(34):1700636. doi: 10.2807/1560-7917.ES.2018.23.34.1700636. Euro Surveill. 2018. PMID: 30153883 Free PMC article.
-
Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16.Euro Surveill. 2019 Jan;24(1):1700818. doi: 10.2807/1560-7917.ES.2019.24.1.1700818. Euro Surveill. 2019. PMID: 30621818 Free PMC article.
-
Effectiveness of meningococcal serogroup C vaccine programmes.Vaccine. 2013 Sep 23;31(41):4477-86. doi: 10.1016/j.vaccine.2013.07.083. Epub 2013 Aug 9. Vaccine. 2013. PMID: 23933336 Review.
-
Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.J Infect. 2024 Sep;89(3):106228. doi: 10.1016/j.jinf.2024.106228. Epub 2024 Jul 10. J Infect. 2024. PMID: 38996818
Cited by
-
Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review.Infect Dis Ther. 2019 Sep;8(3):307-333. doi: 10.1007/s40121-019-0254-1. Epub 2019 Jul 25. Infect Dis Ther. 2019. PMID: 31347097 Free PMC article. Review.
-
Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.Pathog Glob Health. 2022 Mar;116(2):85-98. doi: 10.1080/20477724.2021.1972663. Epub 2021 Sep 27. Pathog Glob Health. 2022. PMID: 34569453 Free PMC article. Review.
-
Meningococcal Disease Outbreaks: A Moving Target and a Case for Routine Preventative Vaccination.Infect Dis Ther. 2021 Dec;10(4):1949-1988. doi: 10.1007/s40121-021-00499-3. Epub 2021 Aug 11. Infect Dis Ther. 2021. PMID: 34379309 Free PMC article. Review.
-
Carbohydrate based meningococcal vaccines: past and present overview.Glycoconj J. 2021 Aug;38(4):401-409. doi: 10.1007/s10719-021-09990-y. Epub 2021 Apr 27. Glycoconj J. 2021. PMID: 33905086 Free PMC article. Review.
-
Bactericidal antibodies against hypervirulent Neisseria meningitidis C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children.Hum Vaccin Immunother. 2021 May 4;17(5):1442-1449. doi: 10.1080/21645515.2020.1833578. Epub 2020 Dec 16. Hum Vaccin Immunother. 2021. PMID: 33325757 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources